Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer

Inclusion criteria

• Histopathologically confirmed primary colorectal adenocarcinoma.
• Radiographic assessment showed a stage II-III based on AJCC Stage 8th ed.
• At least 18 years old.
• MSI-H or dMMR.
• The Eastern Cooperative Oncology Group performance status (ECOG PS) score is 0 or 1.
• Physical state or organ function can tolerate the planned treatment of the study protocol.
• Agreed to sign written informed consent before recruitment.

Exclusion criteria

• Previously received any antitumor therapy for the disease under study, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.
• Pregnancy or breastfeeding women.
• History of other malignancies within 5 years.
• Serious medical illness, such as severe mental disorders, cardiac disease, uncontrolled infection, etc.
• Immunodeficiency disease or long-term using of immunosuppressive agents.
• Allergic to any component of the therapy.
• Any other condition or disease that is not suitable to take the therapy included in the protocol.
• Concurrent participation in another clinical study, unless participating in an observational (non-interventional) clinical study or in the survival follow-up phase of an interventional study.
• Received any investigational drug or device treatment within 4 weeks prior to initial administration of the investigational drug.